Welcome to our dedicated page for Polyrizon Ltd. SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. (PLRZ) completed a registered direct offering and concurrent private placement with a single institutional investor, raising aggregate gross proceeds of approximately $4.0 million.
The transactions involved the sale of 333,333 Units (or Pre-Funded Units), each consisting of one Ordinary Share (or one Pre-Funded Warrant) and one Common Warrant, at $12.00 per Unit (or $11.99999 per Pre-Funded Unit). Polyrizon issued 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants in the registered direct component and 70,833 PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants in the private placement. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share (subject, for unregistered PIPE Pre-Funded Warrants, to registration), and the Common Warrants have a $12.00 per share exercise price. Polyrizon expects to use the net proceeds for general corporate purposes and working capital.
Polyrizon Ltd. (PLRZ) entered into definitive agreements for a combined registered direct offering and concurrent private placement with a single institutional investor, structured as 333,333 units at a combined offering price of $12.00 per unit, for expected aggregate gross proceeds of $4.0 million.
The registered direct component covers the sale of 232,500 Ordinary Shares and 30,000 pre-funded warrants, while the private placement adds 70,833 PIPE pre-funded warrants and 333,333 Ordinary Share Warrants, each warrant exercisable for one Ordinary Share. Pre-funded warrants carry a de minimis exercise price of $0.00001 and no expiration, and all warrants are subject to a 9.99% beneficial ownership cap. Aegis Capital Corp. acts as exclusive placement agent, earning an 8.0% cash fee and $75,000 for expenses. Gross proceeds are expected to support general corporate purposes, including operations, capital expenditures, business development, technology development and potential strategic acquisitions. Assuming exercise of all pre-funded warrants issued in the transactions, Ordinary Shares outstanding would total 2,806,233.
Polyrizon Ltd. (PLRZ) is conducting a shelf takedown under its Form F-3 to sell 232,500 ordinary shares at $12.00 per share and 30,000 pre-funded warrants at $11.99999 each, plus 30,000 ordinary shares underlying those pre-funded warrants. This public offering represents gross proceeds of $3,149,999.70, with placement fees of $251,999.98 and proceeds before expenses of $2,897,999.72. In a concurrent private placement, the company is also issuing 70,833 additional pre-funded warrants and 333,333 unregistered ordinary share warrants, each exercisable at $12.00 per share for five years. Ordinary shares outstanding were 2,139,567 as of September 2, 2026 and are expected to be 2,402,067 after this offering, assuming full exercise of the registered pre-funded warrants. Net proceeds from this offering and the concurrent private placement are estimated at about $3.5 million, to be used for general corporate purposes, including operations, R&D, and potential strategic acquisitions.
Polyrizon Ltd. (PLRZ) reports an operational milestone for its NASARIX™ Allergy Blocker (PL-14) program, having completed contracting with all five U.S. clinical sites for its first-in-human study. The report also incorporates portions of this update by reference into existing Form S-8 and Form F-3 registration statements.
The planned prospective, multicenter, randomized, single-blind, two-arm trial will enroll up to 120 patients with seasonal allergic rhinitis, randomized 1:1 to NASARIX™ or isotonic saline nasal spray. Primary efficacy will be measured by mean daily reflective Total Nasal Symptom Score over the first 14 treatment days, with safety based on treatment-emergent adverse events and tolerability. Polyrizon is now moving into patient pre-screening and enrollment, timed to relevant allergy seasons.
MMCAP International Inc. SPC and MM Asset Management Inc. report passive ownership of ordinary shares of Polyrizon Ltd. They beneficially own 199,470 ordinary shares, representing 9.6% of the outstanding class, based on 2,083,979 issuer ordinary shares outstanding. All voting and dispositive power over these shares is shared between the reporting persons, with no sole voting or dispositive authority. The filing is submitted as Amendment No. 1 to a Schedule 13G, reflecting updated ownership information and includes a joint filing agreement as an exhibit.
Polyrizon Ltd. reports that shareholders approved all proposals presented at the annual general meeting held on July 13, 2026. These approvals were made by the requisite majorities under Israeli Companies Law and the company’s amended and restated articles of association.
A key outcome is the adoption of an amended Compensation Policy for executive officers and directors, which will serve as the company’s compensation framework for three years from July 13, 2026. The policy ties executive pay to Polyrizon’s business and financial long-term goals and allows for base salary, benefits, cash bonuses, equity-based compensation, and various retirement and termination arrangements.
The policy permits up to 12 months’ prior notice of termination for the CEO and chairperson and six months for other executive officers, plus a possible additional adjustment period of up to six months, during which all compensation elements and equity vesting may continue. It also allows non-compete grants and other non-statutory payments, with total non-statutory amounts capped at 24 times an executive’s monthly base salary. Directors and executive officers may also benefit from exculpation, indemnification, and insurance to the fullest extent permitted by law. The 6-K and the full Compensation Policy are incorporated by reference into Polyrizon’s existing Form S-8 and Form F-3 registration statements.
Polyrizon Ltd. reported that its NASARIX/Allergy Blocker nasal spray achieved successful results in a comprehensive biocompatibility evaluation program. All required biological safety tests met their predefined acceptance criteria, supporting the product’s safety profile for intranasal use.
The program followed internationally recognized standards, including the ISO 10993 series, FDA guidance and European regulatory requirements, and assessed biological endpoints, long-term systemic toxicity and toxicological risk based on final product configuration and materials. These non-clinical results are presented as a key milestone toward advancing the device to its first-in-human clinical trial and potential commercialization as a drug-free nasal barrier for managing seasonal allergic rhinitis.
Polyrizon Ltd. reports that it has received central Institutional Review Board (IRB) approval from BRANY to begin its first human clinical trial of NASARIX™, a nasal spray designed to block airborne allergens in people with seasonal allergic rhinitis.
The approved study will compare NASARIX against a saline spray to evaluate efficacy, safety and tolerability, using a master protocol, informed consent documents, quality-of-life assessments and electronic diary tools that have all been cleared by the IRB. The central approval, granted on June 18, 2026, covers the study’s master file through June 17, 2027, while individual clinical sites must still obtain their own site-specific IRB approvals before activating sites and enrolling patients.
Polyrizon Ltd., a development-stage biotech company focused on intranasal hydrogels, reported that a U.S. patent application covering its Trap & Target™ mucoadhesive nasal drug delivery platform has been published as patent application No. US 2024/0358741 A1.
The application describes biocompatible mucoadhesive polymers that form a durable film on mucosal surfaces to enhance retention, absorption, and sprayability for nasal and oral formulations. Potential uses include sprays, gels, inhalation products, and localized or systemic delivery of drugs such as anti-inflammatories, vaccines, biologics, and other active ingredients.
Polyrizon positions this Trap & Target technology alongside its existing Capture and Contain™ hydrogel “biological mask” platform, both aimed at improving nasal barrier protection and drug delivery. The company cautions that there is no assurance any patent will ultimately issue from the pending application.
Polyrizon Ltd. reports a key development for its NASARIX™ (PL-14) Allergy Blocker program. The company has signed agreements with a leading European university medical center and a specialized contract research organization to run a human performance and characterization study.
The single-site study in healthy participants will measure how long the intranasal NASARIX™ hydrogel remains in the nasal cavity, helping estimate the duration of its protective barrier function against allergens. It will follow Good Clinical Practice and European medical device regulations and is intended to support Polyrizon’s broader verification and validation program and planned regulatory submissions, including to the U.S. FDA.